Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer

Onkologie

Volumn 27, Issue 3, 2004, Pages 280-284

  Schmittel, A ^a   Schulze, K ^a   Hutter G ^a   Krebs, P ^a   Thiel, E ^a   Keilholz, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carboplatin; CPT 11; Irinotecan; Phase I trial; Small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RADIOGRAPHY; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 3943082083     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077979     Document Type: Article

References (14)

1. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
2. Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S Segawa Y, Harada M: A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposid (PVP) versus sequential administration of VAV-PVP for the treatment of patients with small cell lung carcinoma: Results of long term follow-up. Cancer 1998;83:283-290.
3. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PJ, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclophosphamide, doxorubicine, and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999;17:658-667.
4. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N: Irinotecan plus Cisplatin compared with etoposide plus cisplatin for extensive small lung cancer. N Engl J Med 2002;346:85-91.
5. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis K, Klouvas G: Randomized comparison of etoposid-cisplatin vs. etoposid-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-607.
6. Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi H, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S: Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 1999;5:3963-3969.
7. Sato M, Ando M, Minami H, Ando Y, Ando M, Yamamoto M, Sakai S, Watanabe A, Ikeda T, Sekido Y, Saka H, Shimokata K, Hasegawa Y: Phase I/II pharmacologic study of irinotecan and carboplatin for patients with lung cancer. Cancer Chemother Pharmacol 2001;48:481-487.
8. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K: A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulcytecolony stimulating factor in the treatment of patients with advanced non small cell lung carcinoma. Cancer 1998;82:2166-2172.
9. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
10. Jelliffe RW: Letter: Creatinine clearance: Bedside estimate. Ann Intern Med 1973;79:604-605.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New giudelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
12. Kehrer DFC, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ: Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136-1141.
13. Kinoshita A, Fukuda M, Fukuda M, Nagashima S, Kuba M, Narasaki F, Takatani H, Kanda T, Kasai T, Tsurutani J, Nakamura Y, Soejima Y, Inoue Y, Soda H, Oka M, Kohno S: A phase II study of irinotecan (CPT-11) and carboplatin (CBDCA) in patients with small cell lung cancer. Proc ASCO 2002;20:1260.
14. Naka N, Kawahara M, Okishio K Hosoe S, Ogawara M, Atagi S, Takemoto Y, Ueno K, Kawaguchi T, Tsuchiyama T, Furuse K: Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-323.